Magnesium trisilicate with Mg carbonate & NaHCO3
Brand names: Magnesium Trisilicate Mixture BP
This antacid combines magnesium trisilicate, magnesium carbonate and sodium bicarbonate to provide short-term relief of dyspepsia, heartburn and acid-related indigestion.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The magnesium salts and sodium bicarbonate neutralise gastric acid and raise intragastric pH, while magnesium trisilicate also reacts to form a gelatinous silica that offers a degree of mucosal protection.
Prescribing in practice
- The sodium bicarbonate content gives a significant sodium load, so it should be used with caution in hypertension, heart failure and other conditions requiring sodium restriction.
- Magnesium salts may accumulate and cause toxicity in renal impairment, and the magnesium component tends to be mildly laxative.
- Antacids can reduce the absorption of many oral drugs, so doses should be separated from other medicines.
Monitoring
No routine monitoring is needed for occasional use, but review sodium intake and renal function if used regularly or in susceptible patients.
Counselling the patient
- Take doses separately from your other tablets, leaving a gap between them.
- This product contains sodium, so mention it if you are on a low-salt diet or have heart or kidney problems.
- See your prescriber if indigestion is persistent or recurrent rather than relying on long-term self-treatment.
Evidence & guidelines
Compound magnesium and bicarbonate antacids are long-standing symptomatic treatments for dyspepsia; persistent or alarm-feature symptoms warrant assessment as advised by NICE dyspepsia guidance.
Reference: Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021